Marksans Pharma UK arm Relonchem gets marketing nod for high BP drug
Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary in UK, Relonchem Limited, has received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its two products.
The latest approvals are part of a broader string of UK MHRA authorizations received by Relonchem throughout the year.
In August, Relonchem received marketing authorisation for three strengths of its Metformin Hydrochloride Relonchem Prolonged Release Tablets.
In June 2025, the subsidiary secured marketing authorization for Oxybutynin hydrochloride 2.5mg/5ml Oral Solution.
In late May, Relonchem received marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution, followed by approval for Sennosides 7.5 mg Tablets earlier in the month.
In March, the UK MHRA approved Baclofen 10 mg Tablets, a medication used to relax specific muscles in the body, relieving spasms, cramps, and tightness associated with multiple sclerosis or spinal injuries.
The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK.
Back in February, Relonchem also received authorization for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets (Bell's Healthcare Dual Action Pain Relief 200 mg/500 mg Film-coated Tablets).
